We are looking for a talented and driven postdoctoral researcher to join our translational oncology research group at Radboudumc, Nijmegen. Our group is committed to developing accurate, data-driven decision support tools for precision immuno-oncology, tailored to individual patients with thoracic malignancies based on tumour and patient characteristics.
You will play a central role in the analysis of biomarker data of the DEDICATION-1 trial (PMID: 38089058), a clinical study in advanced-stage non-small cell lung cancer (NSCLC), with a primary focus on biomarker discovery, development and validation. Your work will directly bridge laboratory findings with clinical application, contributing to a future in which treatment decisions in thoracic oncology are guided by robust, personalized biomarkers.
Your Responsibilities
-
Represent and strengthen the corporate identity of Radboudumc in all scientific and collaborative activities.
-
Take responsibility for structuring, curating, and safeguarding research data, working closely with the research team at the Department of Pulmonary Diseases and Department of Pharmacy, Pharmacology & Toxicology, to ensure that datasets are organized, interoperable, and accessible for future projects beyond individual research interests and act as an ambassador for transparent, collaborative, and sustainable data practices, promoting a culture of open science and long‑term research continuity beyond the scope of personal interests.
-
Lead and execute biomarker development analyses within the DEDICATION-1 trial, integrating multi-omics, immunological, and clinical datasets.
-
Present findings at national and international oncology and immunology conferences, and publish results in peer-reviewed journals.
-
Actively contribute to building and maintaining an (inter)national research consortium, fostering collaborations between Radboudumc, UMCU, and other partner institutions.
-
Identify, write, and apply for competitive grants and fellowships (e.g., NWO, KWF, Horizon Europe, or industry-partnered funding).
Targets for the coming 2 years
-
Biomarker development - Analyse, present, and publish findings from DEDICATION-1.
-
Grant acquisition - Apply for and receive at least one competitive grant or award.
-
Consortium building - Expand the (inter)national research network actively.
-
Scientific output - Contribute to peer-reviewed publications and conference presentations.
-
Data framework - Deliver a structured, documented, and future‑proof data framework for the DEDICATION-1 trial data.
